Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory B-Cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT03575351
What this trial is testing

Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 184
Testing effectiveness (Phase 2)Study completedNCT03259529
What this trial is testing

Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
St. Petersburg State Pavlov Medical University 30
Testing effectiveness (Phase 2)Study completedNCT01481129
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Ended earlyNCT00968331
What this trial is testing

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
University of Bologna 25
Early research (Phase 1)Study completedNCT00003294
What this trial is testing

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

Who this might be right for
LeukemiaLymphomaUnspecified Adult Solid Tumor, Protocol Specific
Roswell Park Cancer Institute 24
Early research (Phase 1)Study completedNCT02219737
What this trial is testing

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
CD20 PositiveRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Study completedNCT01453205
What this trial is testing

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
MedImmune LLC 187
Testing effectiveness (Phase 2)WithdrawnNCT04535102
What this trial is testing

POLA+BR for Relapsed or Refractory DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
University of Colorado, Denver
Testing effectiveness (Phase 2)Study completedNCT04605666
What this trial is testing

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

Who this might be right for
B Cell LeukemiaB Cell Lymphoma
Nanfang Hospital, Southern Medical University 77
Early research (Phase 1)UnknownNCT04008251
What this trial is testing

Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaB Cell Lymphoma
Wuhan Sian Medical Technology Co., Ltd 10
Early research (Phase 1)Not Yet RecruitingNCT07616089
What this trial is testing

Phase I Study of FXS0683 in the Treatment of Blood Tumors

Who this might be right for
B-Cell LymphomaAcute Myeloid LeukemiaMyelodysplastic Syndromes+1 more
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 228
Testing effectiveness (Phase 2)Ended earlyNCT04161118
What this trial is testing

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
University of Cologne 3
Testing effectiveness (Phase 2)Study completedNCT01209286
What this trial is testing

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
B-ALL
Amgen Research (Munich) GmbH 36
Testing effectiveness (Phase 2)Ended earlyNCT06088654
What this trial is testing

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
Innate Pharma 23
Testing effectiveness (Phase 2)Looking for participantsNCT07508605
What this trial is testing

Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital 20
Not applicableStudy completedNCT07103486
What this trial is testing

Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Novartis Pharmaceuticals 264
Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20
Testing effectiveness (Phase 2)Study completedNCT00445341
What this trial is testing

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)WithdrawnNCT03880279
What this trial is testing

Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Triumvira Immunologics, Inc.
Not applicableActive Not RecruitingNCT07709624
What this trial is testing

Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study

Who this might be right for
DLBCL
TTY Biopharm 50
Next Page